Challenges and Opportunities in Italian Corporate Governance

The book examines corporate governance issues from different perspectives (law, business management, accounting and practitioners), assessing the progress made by Italian companies in improving corporate governance and the gaps that remain. Moreover, it presents governance issues in the widely varying perspectives of owners, boards, management, and other stakeholders to-create a complete picture of the Italian corporate governance environment. We have decided to create four sections: l. Corporate governance and firm performance 2. New perspectives of corporate governance 3. The role of CSR and innovation in business strategy 4. Corporate governance in the banking sector Our aim as editors was to achieve a high quality of content so that "Challenges and Opportunities in Italian Corporate Governance" would be seen as an essential reference text in our fi.eld of research. We thank ali the contributors who helped with this project. We hope that this book will give the reader food for thought and we hope that the new project with Virtus Interpress will continue the dialogue among corporate governance specialists

SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study

Background: The MuSC-19 project is an Italian cohort study open to international partners that collects data on multiple sclerosis (MS) patients with COVID-19. During the second wave of the pandemic, serological tests became routinely available. Objective: To evaluate the seroprevalence of anti-SARS-CoV-2 antibodies according to the use of disease-modifying therapy (DMT) in a subset of patients included in the MuSC-19 data set who had undergone a serological test. Methods: We evaluated the association between positive serological test results and time elapsed since infection onset, age, sex, Expanded Disability Status Scale score, comorbidities and DMT exposure using a multivariable logistic model. Results: Data were collected from 423 patients (345 from Italy, 61 from Turkey and 17 from Brazil) with a serological test performed during follow-up. Overall, 325 out of 423 tested patients (76.8%) had a positive serological test. At multivariate analysis, therapy with anti-CD20 was significantly associated with a reduced probability of developing antibodies after COVID-19 (odds ratio (OR) = 0.20, p = 0.002). Conclusion: Patients with MS maintain the capacity to develop humoral immune response against SARS-COV-2, although to a lesser extent when treated with anti-CD20 drugs. Overall, our results are reassuring with respect to the possibility to achieve sufficient immunization with vaccination